SBI US Gateway Fund is the specified investment vehicle named by Sift and Typewriter.
Recorded funding activity
Sift develops peptide immunotherapies using AI and profiling. Typewriter develops RNA-based insertion of therapeutic genes. These financing relationships belong to the named vehicle rather than to every SBI group entity.
Typewriter Therapeutics is developing an all-RNA gene-writing platform that inserts therapeutic genes at a defined genomic site without viral vectors or double-strand DNA breaks. Its programs target in vivo engineered CAR-T cells and gene insertion for severe genetic diseases, including liver disorders.